Drug intelligence / Profile preview

SN-PD07

Development stage: Preclinical
Lead developer: Fountain Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SN-PD07 is an anti-PD-1 monoclonal antibody being developed by Fountain Biopharma for the treatment of neoplasms. Originally developed by Synovel Sciences, which was acquired by Fountain Biopharma in 2017, SN-PD07 is designed to inhibit the Programmed cell death protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands, such as PD-L1, the antibody prevents the down-regulation of T-cell activity, thereby enhancing the immune system's anti-tumor response. The drug is currently in the preclinical stage of development.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SN-PD07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SN-PD07.

Explore the full profile